Physician profile
Natalie Sessions
NPI 1992997175
$2,584.76
in general payments reported to CMS, 2019-2025
26 companies · $1,067 in 2025
The $1,067 reported for 2025 was more than what a typical Rheumatology provider received nationally (typical 2025 total: $894).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $524 · 2020: $137 · 2021: $132 · 2022: $109 · 2023: $204 · 2024: $413 · 2025: $1,067.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,683.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,682.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,102.68 | 2019-2025 | Rinvoq |
| Genzyme Corporation | $350.04 | 2019-2025 | |
| Alexion Pharmaceuticals, INC. | $178.33 | 2023-2024 | |
| Amgen INC. | $164.04 | 2019-2025 | Tavneos, Enbrel, Otezla |
| Pacira Therapeutics, INC. | $116.03 | 2019-2020 | |
| Ucb, INC. | $99.44 | 2019-2025 | Bimzelx |
| Mallinckrodt Hospital Products INC. | $80.14 | 2020-2025 | Acthar |
| Radius Health, INC. | $55.91 | 2019-2025 | Tymlos |
| Janssen Biotech, INC. | $55.12 | 2019-2024 | Tremfya |
| Celgene Corporation | $34.27 | 2019 | |
| Lilly USA, LLC | $32.07 | 2019-2020 | |
| Aurinia Pharma U.S., INC. | $30.55 | 2024 | Lupkynis |
| Sobi, INC | $30.46 | 2019 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $29.69 | 2020 | |
| Fresenius Kabi USA, LLC | $29.55 | 2024 | Idacio |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| E.R. Squibb & Sons, L.L.C. | $28.04 | 2019 | |
| Octapharma USA, INC. | $27.34 | 2025 | Octagam Immune Globulin (Human) |
| Pfizer INC. | $21.64 | 2025 | |
| Novartis Pharmaceuticals Corporation | $18.86 | 2019 | |
| Genentech USA, INC. | $16.99 | 2019 | |
| Ferring Pharmaceuticals INC. | $14.62 | 2019 | |
| Sebela Pharmaceuticals INC. | $14.44 | 2019 | |
| Hikma Pharmaceuticals USA | $14.44 | 2019 | |
| Mallinckrodt Enterprises LLC | $14.39 | 2019 | |
| Horizon Therapeutics Plc | $13.70 | 2019 | |
| Glaxosmithkline, LLC. | $11.98 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Natalie Sessions listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.